4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-018336
PRESIDENT AND CEO sold 12,000 shares at an average $21.66 ($259,902)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Kintz Samuel · PRESIDENT AND CEO
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-06-25 | Sale : show line 1 in the form 10b5-1 | −11,422 | $21.63 | $247,014 | 1,076,103 | I |
| 2024-06-25 | Sale : show line 2 in the form 10b5-1 | −578 | $22.30 | $12,887 | 1,075,525 | I |
| Open-market sales · 12,000 sh · avg $21.66 · $259,902 | ||||||
Loading xslF345X05/form4-06272024_080620.xml…